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Association of MYH9-rs3752462
polymorphisms with chronic kidney disease
among clinically diagnosed hypertensive
patients: a case-control study in a Ghanaian
population
William K. B. A. Owiredu1, Michael Appiah1*, Christian Obirikorang1, Evans Asamoah Adu1, Vincent Boima2,
Ernestine Kubi Amos-Abanyie3, Priscilla Abena Akyaw3, Eddie-Williams Owiredu1 and Emmanuel Acheampong1,4
Abstract
Background: Chronic kidney disease (CKD) is a significant comorbidity among hypertensive patients.
Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) have been demonstrated to be significantly
associated with CKD, among African- and European-derived populations. We investigated the spectrum of MYH9-
associated CKD among Ghanaian hypertensive patients.
Methods: The study constituted a total of 264 hypertensive patients. Hypertensive patients with glomerular
filtration rate (eGFR) < 60 ml/min/1.73m2 (CKD-EPI formula) or clinically diagnosed were defined as case subjects
(n = 132) while those with eGFR ≥60 ml/min/1.73m2 were classified as control subjects (n = 132). Demographic data
were obtained with a questionnaire and anthropometric measurements were taken. Five (5) millilitres (ml) of
venous blood was drawn from study subjects into gel and EDTA vacutainer tubes. Two (2) mL of EDTA
anticoagulated blood was used for genomic DNA extraction while three (3) mL of blood was processed to obtain
serum for biochemical measurements. Genotyping of MYH9 polymorphisms (rs3752462) was done employing Tetra
primer Amplification Refractory Mutation System (T-ARMS) polymerase chain reaction (PCR). Spot urine samples
were also collected for urinalysis. Hardy-Weinberg population was assessed. Logistic regression models were used
to assess the associations between single nucleotide polymorphisms and CKD.
Results: The cases and control participants differed in terms of age, sex, family history, and duration of CKD (p-
value < 0.001). The minor allele frequencies of rs3752462 SNP were 0.820 and 0.567 respectively among the control
and case subjects. Patients with the heterozygote genotype of rs3752462 (CT) were more likely to develop CKD
[aOR = 7.82 (3.81–16.04)] whereas those with homozygote recessive variant (TT) were protective [aOR = 0.12 (0.06–
0.25)]. Single nucleotide polymorphism of rs3752462 (CT genotype) was associated with increased proteinuria,
albuminuria, and reduced eGFR.
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Conclusions: We have demonstrated that MYH9 polymorphisms exist among Ghanaian hypertensive patients and
rs3752462 polymorphism of MYH9 is associated with CKD. This baseline indicates that further longitudinal and
multi-institutional studies in larger cohorts in Ghana are warranted to evaluate MYH9 SNP as an independent
predictor of CKD among hypertensive patients in Ghana.
Keywords: Chronic kidney disseise, Hypertension, Single nucleotide polymorphism, MYH9- rs3752462
Background
The antecedents of mortality rate in Africa have shifted
in recent years from communicable diseases to a com-
bination of chronic non-communicable diseases (NCDs)
and communicable conditions especially, in Ghana [1].
According to the World Health Organisation reports in
2018, 43% of all mortality rates in Ghana are attributed
to NCDs [2]. High blood pressure affects entirely 1.13
billion people worldwide and most (approximately 67%)
live in low- and middle-income countries [3]. Also,
about 6% of people living with hypertension have
chronic kidney disease (CKD) and are at risk for pro-
gression to end-stage renal disease (ESRD) [4]. Thus, the
future risk of NCD forms of CKD, predominantly driven
by increased rates of hypertension, is a growing public
health concern. In sub-Saharan Africa, an alarmingly
32.3% of hypertensive patients have CKD [5].
CKD has been reported to be predominant among
hypertensive patients in the Ghanaian population. For
instance, Osafo, Mate-Kole [6] reported a CKD preva-
lence of 46.9% among hypertensive patients from four
polyclinics in Accra, Ghana. Also, among the population
from the south-western part of Ghana, CKD prevalence
is reportedly 22% among hypertensive patients [7]. Add-
itionally, renal impairment was observed at a rate of 25,
9.5, and 10.5% among hypertensive patients in a District
hospital, utilizing Cockcroft Gault (CG), Four-Variable
Modification of Diet in Renal Disease (4v-MDRD) and
the Chronic Kidney Disease-Epidemiology Collaboration
(CKD-EPI) equations, respectively [8]. A more recent
multicentre cross-sectional study among Ghanaian
hypertensive patients reported a CKD prevalence rate of
26.3% [9].
The introduction of genome-wide association studies
(GWAS) has made important contributions to the dis-
covery of genes contributing to hypertensive nephropa-
thy (HN) [10]. Recently, a published study uncovered a
new approach to the pathogenesis of CKD among the
African American population [11]. While Kao et al. re-
ported a significant association between MYH9 point
mutations and the risk of CKD [12], Bostrom and Freed-
man present a common theme that “risk variants of
MYH9 could be a major determinant of excess risk of
CKD associated with African ancestry” [13]. The
spectrum of MYH9-associated nephropathy is such that
MYH9 risk variants exhibit the most remarkable rela-
tionship with every common complex kidney disease
identified. It also signifies a bias marker on ethnic differ-
ences in clinical outcomes [13].
The importance of the MYH9 polymorphisms in the
context of CKD is that there is enough evidence in the
literature of being a causal variant for CKD in diabetics
[14], Lupus Nephritis [15], and non-diabetic population
[16, 17]. Aside from the major translational benefits of
finding genetic risk variants associated with CKD, they
are also likely novel therapeutic targets and also enhance
our understanding of disease pathogenesis. No published
study has assessed MYH9 polymorphisms and the risk
of CKD among hypertensives in the Ghanaian popula-
tion to be the very best of our knowledge. We, therefore,
investigated the transferability of the MYH9-rs3752462
gene polymorphism in terms of its association with CKD
among Ghanaian hypertensive patients.
Methods
Study design and population
The study was a case-control one conducted between
January 2018 and June 2019 at Korle-Bu Teaching Hos-
pital (KBTH) with eligible participants drawn from the
hypertension clinic and renal unit. A total of 264 hyper-
tensive patients comprising of 132 case group and 132
control group were included for the study. Hypertensive
patients aged 18 years and above without history/signs
or clinically diagnosed CKD and Glomerular filtration
rate (eGFR) ≥ 60 ml/min/1.73 m2 (CKD-EPI formula)
classified as control subjects. Hypertensive patients aged
18-years and above with Glomerular filtration rate
(eGFR) < 60 ml/min/1.73 m2 (CKD-EPI formula) or
clinically diagnosed CKD. CKD cases of unknown origin
were excluded from the study. Cases and control
participants with comorbid diabetes and accelerated
hypertensive patients were excluded from the study.
Sample size justification
The sample size for the study was calculated using the
Cochran–Armitage trend tests [18]. By considering the
additive genetic model at a case: control ratios of 1:1,
the rare allele frequency of 0.5, and CKD prevalence of
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26.3% among hypertensive patients [9], the sample size
needed to achieve the prespecified 0.05 α-level and a
power 80 for a two-sided trend test was 264 (132 cases
vs 132 controls).
Anthropometric measurement
An automated sphygmomanometer (OMRON
HEM705CP; Omron Matsusaka Co, Matsusaka, Japan)
was used for the measurements of blood pressure (BP).
Three consecutive readings of blood pressure measure-
ments were taken from the patients’ right arm and the
mean of two closest values was recorded. Controlled
blood pressure was defined as BP < 140/90mmHg. Body-
weight of all participants expressed in 0.1-Kg intervals
was taken at a fasting state using an automated
weighing scale. Portable height rod stadiometers were
used for height measurements to the nearest centi-
metre. BMI was calculated as the ratio of body weight
to height (Kg/m2).
Blood sample collection
Five millilitres (5 mL) of the venous blood sample was
collected from each participant. Three (3) mL of blood
collected into BD vacutainer® gel tubes and 2mL into a
tube containing 2.5 μg of dipotassium ethylenediamine-
tetraacetic acid (K2 EDTA) as an anticoagulant. Serum
preparation was done on the blood samples in the gel
tube and stored at − 80 °C until assayed. EDTA samples
were processed immediately for gDNA extraction.
Urinalysis
Early morning urine or spot urine was collected into
wide-mouth plastic containers from the respondents and
urine protein, albumin, and urine creatinine levels were
estimated using a complete chemistry auto-analyser
(SELECTRA Pro S) with Ellitec reagents (Namarka,
Germany).
Biochemical assay
Serum samples were analysed for urea, creatinine, fasting
blood sugar, total cholesterol, LDL-cholesterol, HDL-
cholesterol, and Triglycerides using the SELECTRA Pro
S chemistry analyser, (ELITechGroup, France).
Dyslipidemia was defined when subjects had either of
the following: total cholesterol ≥ 200 or triglyceride 150
mg/dL (1.7 mmol/L) or high-density lipoprotein < 40
mg/dL (1.03 mmol/L) in male < 50mg/dL (1.29 mmol/L)
in females. Hyperglycaemia: Fasting glucose levels
≥6.1 mmol/L.
Sample processing for DNA analysis
Genomic DNA was extracted from EDTA peripheral
blood using the Quick-gDNATM Blood Miniprep Kit
(Zymo, Hilden, Germany) following the manufacturer’s
protocol and quantified using a NanoDrop 1000 spectro-
photometer (Thermo Scientific, Waltham, MA, USA).
The DNA samples were amplified using the Tetra pri-
mer Amplification Refractory Mutation System (T-
ARMS) polymerase chain reaction (PCR).
Primer design for T-ARMS PCR
The principle of the primer design was based on the use
of 2 primer pairs (one pair specific to the area of amplifi-
cation and the other pair specific to the SNP of interest)
to amplify and produce specific band sizes consistent to
the particular genotype of the sample being studied all
in one single PCR reaction. The primers for this study
were designed using PCR Designer for Restriction Ana-
lysis of Polymorphism (http://primer1.soton.ac.uk/pri
mer.html) for T-ARMS-PCR as described in [19] The
primers used, band sizes and melting temperature is
shown in Table 1.
T-ARMS PCR genotyping
PCR reaction was performed in a BIO-RAD PTC-220
thermocycler (Dyad MJ Research) for 45 cycles at an ini-
tial denaturation temperature of 95 °C for 5 min, final
denaturation at 94 °C for 3 min, annealing at 73 °C for
45 s with decreasing temperature of 0.5 °C per each
cycle, initial extension at 72 °C for 3 min and a final ex-
tension at 72 °C for 8 min. PCR reactions were carried
out in a total volume of 25 μL containing 12.50 μl of
Quick-Load 2x Master mix with standard buffer
(England Biolabs), 0.5 μM of each of the four primers,
4.0 μM of DNA template and 3.25 uL of sterilized
nuclease-free water. Reactions were done twice to evalu-
ate the consistency of the banding patterns for all
isolates studied. Products were separated on a 2% (w/v)
agarose gel in 1x TAE buffer (40 mM Tris-acetate, 1 mM
EDTA, pH 8.0) at 80 V for 2 h (Fig. 1).
Table 1 Primers for rs3752462 genotyping
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Statistical analysis
All data was entered into Microsoft Excel and double
cleaned for multiple entries. Continuous variables were
expressed as means ± SD and categorical data were
expressed as absolute numbers and proportions. T-test
and Wilcoxon signed-rank tests were used to analyze
the differences in biochemical and anthropometric pa-
rameters between the case and control groups. The
Hardy-Weinberg equilibrium analysis of the SNPs was
conducted using the Chi-squared test. The genotype and
allelic frequencies of SNPs were also assessed by the
Chi-squared test. To test for associations between CKD
and MYH9-rs3752462SNP, logistic regression models
were fitted, where each SNP was presented as a pre-
dictor variable whose values were equal to the number
of copies of the minor allele (0, 1, 2) in an additive
model, or presence of at least one copy of the minor al-
lele (0, 1) in a dominant model or presence of two copies
of the minor allele (0, 1) in a recessive model. Sex, age,
family history of CKD, BP status, and lipid measure-
ments were included as covariates in the fitted model.
The structure of the model was represented as:
Logit [pr (D = 1)] = α + β 1 G + β 2 sex + β 3 age + β 4
family history + β 5 BP status + β 5Lipid measurements.
Where D denotes CKD phenotype; G denotes SNP
coded as an additive, dominant or recessive; β denotes
the corresponding coefficient for each variable in the
model (SNP, sex or age or family history or BP status or
BMI or TC or HDL-C or LDL-C), and its exponential
was the corresponding odds ratio.
Results
Table 2 shows the comparison of the basic characteris-
tics between the case and control subjects. The mean
age of the control subjects was higher compared to the
case subjects (p < 0.0001). There were more male subjects
than females in the case group whereas more females were
found in the control group (p-value < 0.0001). A family
history of CKD was present in 11.4% of the study case
group compared to 0.8% among the control group
(p < .0001).
Metabolic characteristics of the study participants
No significant difference was evident between cases and
control subjects in terms of BMI, TG, and fasting glu-
cose levels (p > 0.05). There were significant differences
between cases and control subjects in all serum analytes
and derived ratios (p < 0.05) other than those stated
above. The systolic and diastolic blood pressure of cases
and control subjects differed significantly < 0.005) and
were found to be above the recommended cut-off for
controlled BP (< 140/90) (Table 2).
Overweight/obesity was high among the case subjects
compared to that of the control subjects (94.7% vs
75.8%, p < 0.0001). Also, uncontrolled blood pressure
was more observed in the case subjects compared with
the control subjects (p < 0.01). Microalbuminuria was
statistically significantly higher in the control group than
what was observed for the case group (93.9% vs 23.5%, p <
0.0001), whereas clinical albuminuria was more observed
among cases than controls (69.7% vs 4.7%, p < 0.0001).
Genotype and Allele Frequencies of rs3752462 SNP
among Cases and Control Group.
The frequency of the CT genotype of rs3752462 was
significantly higher among case subjects compared to
control subjects (80.3% vs 31.8%, p < 0.000. However, the
TT genotype of rs3752462 was more frequent among
control participants compared with cases (65.9% vs
17.4%, p-value < 0.0001). The frequency of the minor al-
lele (T) was high and equivalent in both groups (97.7%).
Fig. 1 A representative image showing 2% (w/v) agarose gel electrophoresis of T-ARMS Genotyping
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The genotype frequencies rs3752462 SNPs among the
case group deviated from Hardy–Weinberg equilibrium
(p-value < 0.0001) (Table 2).
Table 3 shows the frequencies, odds ratios, and p-
values of the rs3752462 genotypes among cases and
controls under recessive, dominant, co-dominant,
additive, and allele models. As shown in Table 2, age,
sex, family history of CKD, blood pressure status and
some biochemical analytes were significant effect
modifiers. The effect of these modifiers was con-
trolled for in our fitted regression model.
The statistical analyses showed that there is a signifi-
cant difference between the two groups under the reces-
sive and co-dominant models. However, there was no
significant difference between the two groups under the
dominant and additive models. Under the co-dominant
model, rs3752462 was associated with CKD in both the
unadjusted [cOR = 8.73 (4.97–15.36)] and adjusted
Table 2 Characteristics of the study participants
Variables Controls (n = 132) Cases (n = 132) P-values
Age (years)a 45.9 ± 14.5 61.7 ± 11.7 < 0.0001
Gender
Male 24 (18.2) 77 (58.3) < 0.0001
Female 108 (81.8) 55 (41.7) < 0.0001
Family history of CKD 1 (0.8) 15 (11.4) < 0.0001
Anthropometric indicesa
BMI (Kg/m2) 32.2 ± 9.4 35.3 ± 15.8 0.053
SBP (mmHg) 142.4 ± 22.6 167.2 ± 29.5 < 0.0001
DBP (mmHg) 87.6 ± 13.4 97.4 ± 21.6 < 0.0001
Biochemical analytes
Total cholesterol (mmol/L)a 5.0 ± 1.1 4.5 ± 1.3 0.001
Triglycerides (mmol/L)a 1.39 ± 0.67 1.45 ± 0.71 0.455
HDL-C (mmol/L)a 1.62 ± 0.30 1.40 ± 0.46 < 0.0001
LDL-C (mmol/L)a 2.73 ± 0.99 2.45 ± 1.15 0.035
Glucose (mmol/L)a 5.6 ± 1.21 5.5 ± 1.3 0.518
Urea (mg/dl)a 4.0 ± 1.1 19.0 ± 8.72 < 0.0001
Creatinine (mg/dl)b 71.0 ± 13.0 889.1 ± 533.76 < 0.0001
Urinary protein (mg/dl)b 210.0 (120.0–285.0) 530.0 (360.0–760.0) < 0.0001
Urinary Albumin (mg/dl)b 10.0 (10.0–20.0) 110.0 (35.0–280.0) < 0.0001
Urinary Creatinine (mg/dl)b 151.5 (72.6–223.3) 163.6 (107.4–253.0) 0.021
uACR (μg/mg)b 92.0 (65.9–172.0) 729.1 (144.3–1783.3) < 0.0001
uPCR (mg/mg)b 1.40 (0.90–2.10) 3.05 (1.63–5.30) < 0.0001
Overweight/Obesity 100 (75.8) 125 (94.7) < 0.0001
Uncontrolled BP 47 (35.6) 81 (61.4) < 0.0001
Hyperglycaemia 34 (25.8) 42 (31.8) 0.277
Dyslipidaemia 66 (50.0) 70 (53.0) 0.712
Microalbuminuria (μg/mg) 124 (93.9) 31 (23.5) < 0.0001
Macroalbuminuria (μg/mg) 6 (4.5) 92 (69.7) < 0.0001
rs3752462
CC 3 (2.3) 3 (2.3) 1.000
CT 42 (31.8) 106 (80.3) < 0.0001
TT 87 (65.9) 23 (17.4) < 0.0001
MAF 0.820 0.576 < 0.0001
aVariables are presented as mean ± SD and compared using t-test; brepresents values presented in median (interquartile ranges) and compared using Mann–
Whitney test. Unless otherwise stated, all variables are presented as frequencies and compared using the Chi-square test. Italicized values represent statistically
significant values. BMI body mass index, uACR urine albumin-creatinine ratio, uPCR urine protein-to-creatinine ratio
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model [aOR = 7.82 (3.81–16.04)]. However, under the re-
cessive model, rs3752462 was protective of CKD in both
the unadjusted and adjusted model (p-value < 0.001).
We compared the distribution of rs3752462 gene vari-
ants by CKD stages. Due to small numbers, stage 3A
&B, as well as Stage 4&5, were combined. The propor-
tion of TT variants was higher (> 50%) among hyperten-
sive patients in Stage 1 and 2 of CKD. Also, the
percentage of the CT genotype was higher (> 60%)
among patients at the extreme stages. The minor allele
frequencies (T) were 72.6 and 87.2%, among patients in
Stage 1, 2, respectively. Also, among patients grouped as
3a&b and 4&5, the minor allele frequencies were re-
spectively, 50.0 and 58.6% (Fig. 2).
We compared the features of renal abnormalities
among patients with CT and TT genotype and the re-
sults presented in Table 4. The levels of serum
creatinine, urea, uPCR, and uACR, were high among
participants with the CT genotype compared with those
with the TT genotype (p-value < 0.01). Urine creatinine
levels did not differ between the two groups (Table 4).
Discussion
The future risk of NCD forms of CKD, predominantly
driven by increased rates of hypertension, is a growing
public health concern in Ghana [6–9], and in some
African countries, it is a death sentence [20]. Although
the epidemiology of CKD in Africa is well elucidated to
some extent [21], current evidence has uncovered new
approaches to understanding the pathogenesis of CKD
[11]. MYH9- rs3752462 polymorphism by far has pro-
duced an impressive association with CKD among dia-
betics [14], Lupus Nephritis [15], and non-diabetic
population [16, 17]. However, there is an extreme
Table 3 Frequencies, odds ratios, and p-values of rs3752462genevariants among cases and controls under recessive, dominant, co-
dominant, additive and allele models
Model Allele Controls (n = 132) Cases (n = 132) cOR (95% CI) aOR (95% CI)
Dominant model wt/mt CT +mt/mt TT 97.7% 97.7% 1 1
wt/wt CC 2.3% 2.3% 1.00 (0.20–5.05) 1.10 (0.19–6.29)
Recessive wt/mt CT + wt/wt CC 34.1% 82.6% 1 1
mt/mt TT 65.9% 17.4% 0.11 (0.06–0.19)** 0.12 (0.06–0.25)**
Co-dominant model wt/mt CT +mt/mt TT 68.2% 19.7% 1 1
wt/mt CT 31.8% 80.3% 8.73 (4.97–15.36)** 7.82 (3.81–16.04)**
Additive model 1 wt/mt CT 93.3% 97.2% 1 1
wt/wt CC 6.7% 2.8% 0.40 (0.08–2.04) 0.41 (0.07–2.44)
Additive model 2 mt/mt TT 96.7% 88.5% 1 1
wt/wt CC 3.3% 11.5% 3.78 (0.71–20.0) 4.0 (0.64–24.89)
Allele Model T-allele 97.7% 97.7% 1 1
C-allele 34.1% 82.6% 9.16 (5.15–16.30)** 8.29 (4.0–17.27)**
mt mutant type, wt; ild type, CI confidence interval, cOR crude odds ratio, aOR adjusted odds ratio (adjusted for age, sex, family history of CKD, hypertensive
control status, BMI, TC, HDL-C, LDL-C); ** p-value < 0.001
Fig. 2 A representative image of the distribution of rs3752462 gene variants stratified by CKD stages. MAF- minor allele frequency
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limitation of data on SNP of MYH9-rs3752462 associ-
ated CKD in the Ghana population. We, therefore, pro-
vide baseline evidence of MYH9-rs3752462 gene
polymorphism among Ghanaian hypertensive patients
and evaluated its association with CKD.
Our findings indicated that there is an excess of the
minor allele (MAF) of rs3752462 among the case and
control subjects (57.6% vs. 82.0%). Likewise, our results
also revealed that heterozygote genotype (CT) of
rs3752462 was predominant among case subjects while
the homozygote recessive (TT) genotype of rs3752462
was more frequent among control subjects. The ob-
served frequencies are higher compared to the reports
from a study by Oleksyk et al. who noted that Africans
have the lowest heterozygosity for rs3752462 (23.2%)
compared to the Americans (42.4%), South Central
Asians (51.9%), East Asians (38.1%), Europeans (41.4%)
and Middle East (43.8%) population, based on evidence
of historical selection in Africa [22].
Oleksyk et al. [22] further described that this observa-
tion among the African population may be a conse-
quence of natural selection but should only be
interpreted in conjunction with other indicators of a se-
lective sweep. Furthermore, the population frequencies
of SNP rs3752462 from 1000 genomes were 4.4% for the
homozygote dominant (CC), 36.3% for the heterozygote
(CT), and 59.3% for the homozygote recessive (TT) re-
spectively. Nevertheless, the minor allele from 1000 ge-
nomes has the highest frequencies in Africa (78.6%) and
Middle East (79.3%) [23], which is similar to our obser-
vation among Ghanaian hypertensive patients.
Familial aggregation of end-stage renal disease has
been demonstrated to be the strongest in the African-
American population [15, 24]. It becomes apparent that
CKD susceptibility from systemic disorders could have
an inherited basis [13] and understanding of the distri-
bution of risk genes among a population serves an im-
portant tool for genetic studies. Similar to other related
studies [17, 25], we observed that MYH9 polymorphic
variant rs3752462 is closely associated with CKD among
hypertensive patients in Ghana. Patients with the hetero-
zygote (CT) genotype of rs3752462 were associated with
8-times increased likelihood of developing CKD even
when covariates and other related risk factors were con-
trolled. However, patients with the homozygote recessive
genotype (TT) were likely protective of CKD. These
findings are consistent with the findings of Tavira et al.
[17] who indicated that SNP rs3752462 is an independ-
ent predictor of reduced eGFR in the Spanish RENAS-
TUR population. Hence, SNP rs3752462 may be
associated with CKD in Ghanaian hypertensive patients.
For the reason that CKD is often silent until late stages,
genotyping of MYH9-rs3752462 among Ghanaian
hypertensive patients could help identify susceptible pa-
tients for prevention.
A study by Tavira et al. [17] amplified the transcripts
from heart tissues of patients who are heterozygotes for
rs3752462, with primers that matched exons 12 and 14
and found a single PCR band that corresponded to a
normal MYH9 sequence. The authors concluded that
the lack of aberrant transcripts suggested a lack of effect
on pre-mRNA splicing, which appears that rs3752462
enhances CKD susceptibility by regulatory effect rather
than functional effect. Besides, the effect of rs3752462
and for that matter, MYH9 gene on CKD has been at-
tributed to linkage disequilibrium with functional SNP
variants in other related studies, where APOL1 variants
have become the major theme for discussion [16, 26]. In
this study, individuals with the heterozygote variant of
rs3752462 had significantly lower eGFR compared to
those who are homozygote recessive. Additionally, ma-
jority of patients with CKD stages 3, 4, or 5 had the CT
genotype of rs3752462. This observation has been dem-
onstrated in a previous study [17], where patients with
the minor allele of rs3752462 were more likely to have
reduced eGFR < 60ml/ min./1.73m2 after adjusting for
the effect of age, gender, and lipid profile.
We also observed that patients with the CT genotype
of SNP rs3752462 of the MYH9 gene showed character-
istics of high uACR, uPCR, and high urine albumin and






Urea (mmol/l) 12.4 (5.4–22.3) 4.20 (3.3–5.9) < 0.0001
Urine protein (mg/dl) 450.0 (235.0–710.0) 270.0 (170.0–370.0) < 0.0001
Urine Albumin (mg/dl) 50.0 (10.0–210.0) 10.0 (10.0–30.0) < 0.0001
uPCR (mg/mg) 2.70 (1.43–9.40) 1.60 (1.00–2.30) < 0.0001
uACR (μg/mg) 395.3 (122.2–1376.9) 92.0 (67.3–175.4) < 0.0001
Serum Creatinine (mg/dl) 538.9 (84.5–1073.2) 75.8 (66.6–94.1) < 0.0001
Urine Creatinine (mg/dl) 140.1 (94.4–237.6) 169.1 (115.3–245.4) 0.290
uACR urine albumin-creatinine ratio, uPCR urine protein-to-creatinine ratio. All values are presented as median (interquartile ranges) and compared using the
Mann Whitney Test. Italized values represent statistically significant values
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protein excretion levels. One key feature of MYH9 gene
mutation in the podocyte and mesangial cells is that it
disrupts the cytoskeleton and causes membrane instabil-
ity [27]. Thus, abnormalities of the MYH9 gene may ex-
plain the presence of proteinuria and the evolution of
CKD in patients affected [28, 29]. It has been shown that
30.0% of all patients who have the MYH9 gene mutation
exhibit renal derangements [30], characteristics of early-
onset proteinuria, and rapid progression to CKD [29].
More so, nephropathy associated with mutation of the
MYH9 gene usually progresses to terminal CKD around
the age of 30 years, yet cases of more advanced age have
been described [31]. Thus, screening for MYH9 gene
mutations in the Ghanaian population could enhance
the detection of CKD susceptible cases. Although the
rs3752462 T allele (CT + TT genotypes) were statistically
significant and our sample sizes were enough to reach a
power 80, our work was based on a limited number of
individuals from a single Ghanaian population.
Collectively, our findings are consistent with reports
from other studies, however, we should mention here
that the study had some limitations. The study has a
small sample size and cases in this present study were
defined as hypertensive patients with CKD and no spe-
cialized test or renal biopsies were performed to exclude
other secondary causes other than diabetes and HIV.
Subjects with primary glomerular disease or CKD of un-
known etiology (CKDu) were excluded even though
renal damage of hypertension diagnosed by clinicians
may often not be related to systemic hypertension.
Conclusions
We have demonstrated that MYH9 polymorphisms exist
among Ghanaian hypertensive patients and rs3752462
polymorphism of MYH9 is associated with CKD. This
baseline indicates that further longitudinal and multi-
institutional studies in larger cohorts in Ghana are
warranted to evaluate MYH9 SNP as an independent
predictor of CKD among hypertensive patients in Ghana.
Screening for MYH9- rs3752462 risk variants may even-
tually be useful in the Ghanaian population, especially
high-risk populations such as hypertensives with or
without a family history of CKD.
Abbreviations
MYH9: Non-muscle myosin heavy chain 9 gene; CKD: Chronic kidney disease
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